BridgeBio Pharma, Inc. (BBIO) — Financial statements
Income statement, balance sheet, and cash flow for BridgeBio Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 502↑126.3% | 222↑2285.3% | 9↓88.0% | 78↑11.4% | 70 | |
| Cost of Revenue | 28↑629.1% | 4↑58.5% | 2↓28.8% | 3↑10.3% | 3 | |
| Gross Profit | 474↑117.3% | 218↑3079.6% | 7↓90.8% | 74↑11.4% | 67 | |
| Operating Expenses | ||||||
| R&D Expenses | 478↓5.7% | 506↑11.1% | 456↑14.1% | 399↓11.4% | 451 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 555↑92.1% | 289↑91.9% | 151↑5.2% | 143↓25.5% | 192 | |
| Other Expenses | 10↓34.5% | 16↑96.9% | 8↓81.9% | 44 | 0.00 | |
| Operating Expenses | 1,043↑28.6% | 811↑32.0% | 614↑4.7% | 586↓8.8% | 643 | |
| Total Costs & Expenses | 1,071↑31.5% | 815↑32.1% | 617↑4.5% | 590↓8.7% | 646 | |
| Operating Results | ||||||
| Operating Income | -569↑4.0% | -593↑2.4% | -607↓18.6% | -512↑11.2% | -577 | |
| Depreciation & Amortization | 9↑48.1% | 6↓6.5% | 6↓4.1% | 7↑15.9% | 6 | |
| EBITDA | -673↓54.0% | -437↑22.7% | -565↓42.3% | -397↑25.5% | -534 | |
| EBIT | -682↓54.0% | -443↑22.6% | -572↓41.5% | -404↑25.1% | -540 | |
| Interest & Other Income | ||||||
| Net Interest Income | -33↑59.5% | -82↓29.7% | -63↑13.2% | -73↓59.7% | -46 | |
| Interest Income | 20↑15.1% | 17↓4.4% | 18↑139.2% | 8↑565.7% | 1 | |
| Interest Expense | 53↓46.5% | 99↑22.1% | 81↑1.1% | 80↑72.0% | 47 | |
| Non-Operating Income | 113↑175.2% | -150↓323.8% | -35↑67.2% | -108↓192.2% | -37 | |
| Other Income / Expenses | -166↓426.7% | 51↑210.7% | -46↓266.5% | 28↑380.5% | -10 | |
| Income Before Tax | -735↓35.6% | -542↑17.0% | -653↓34.8% | -485↑17.4% | -586 | |
| Income Tax Expense | 0.56↓51.9% | 1 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -736↓35.4% | -543↑16.8% | -653↓34.8% | -485↑17.4% | -586 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -729↓36.1% | -536↑16.7% | -643↓33.7% | -481↑14.5% | -563 | |
| Bottom-Line Net Income | -729↓36.1% | -536↑16.7% | -643↓33.7% | -481↑14.5% | -563 | |
| EPS (Basic) | -3.79↓31.6% | -2.88↑27.1% | -3.95↓17.9% | -3.35↑14.1% | -3.90 | |
| EPS (Diluted) | -3.79↓31.6% | -2.88↑27.1% | -3.95↓17.9% | -3.35↑14.1% | -3.90 | |
| Weighted Average Shares | 197↑6.0% | 186↑14.3% | 163↑10.4% | 147↑2.2% | 144 | |
| Weighted Average Diluted Shares | 197↑6.0% | 186↑14.3% | 163↑10.4% | 147↑2.2% | 144 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.